Optimi Health Corp. OPTH
2.21 USD +0.08 (+4.00%)
At closeNov 4, 2026, 4:00 PM EST
2.21 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
1.90 Day range 2.30
1.90 52-week range 6.40
- YTD
- -63.65%
- 1 year
- -63.65%
- Market cap
- 12.65M
- EPS (ttm)
- -1.56
- YTD return
- -63.65%
- 1-year return
- -63.65%
- Volume
- 99.87K
- Avg volume
- 40.35K
- Open
- 2.11
- Previous close
- 2.13
- Day's range
- 1.90 – 2.30
- 52-week range
- 1.90 – 6.40
2Y -4.00 (-65.79%)
Financials — quick view
OPTH Revenue — quarterly 140.20K
OPTH Net income — quarterly -2.40M
OPTH EPS — quarterly -0.56
News
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity 
Optimi Health Completes Latest Production Batch Of Its MDMA Finished Drug Product; Proposed Phase 3 Trial Expected To Begin In 2027 
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia 
Optimi Health to Present at the ThinkEquity Conference 
Optimi Health Appoints Melanie Pump to Board of Directors 
Optimi Health Corp. (NASDAQ:OPTH) Stock Short Interest Jumps 109.1% 
Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia 
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply 
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer 
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial
Your note
Sign in to keep a note on OPTH — it syncs with the Stock Master app.